Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kura launches with $60m to revive Janssen's tipifarnib

This article was originally published in Scrip

Executive Summary

Kura Oncology raised $60m in a private placement and plans to complete a reverse merger into a public company to support Phase II clinical trials for tipifarnib, a drug for which Johnson & Johnson's Janssen subsidiary suspended development in multiple cancer indications in 2008.

You may also be interested in...



Kura May Have Found A Place For Tipifarnib In Head-And-Neck Cancer

The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.

Finance Watch: Ayala Launches First Biopharma IPO In May

The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m. 

Kura Oncology's Troy Wilson On Precision Medicine For Cancer

Since using a reverse-merger last year to go public, Kura Oncology has resurrected an abandoned Janssen cancer candidate and raised $46.5m in an IPO. CEO Troy Wilson spoke with Scrip about the firm's efforts toward precision medicine in cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel